Hanno Ronte

We recently hosted a virtual roundtable with 14 senior executives on 18th July, exploring what it takes to deliver a successful transformation. Simon Henderson, Mohit Wadan, and Fritz Jaeger from Bain's Performance Improvement and Accelerated Transformation team led an insightful session, discussing six key features for success. They highlighted the importance of focusing on productivity, covering both growth and cost, to stay competitive in all seasons. Balancing "change the business" and "run the business" activities was also emphasized for sustained efficiency. https://bit.ly/3WwDORG

1

Discover insights from Emilio Domingo, Head of Private Equity in the UK, as he discusses the outlook for private equity in 2024 in our latest webinar recording: Global Private Equity Report: UK and Europe deep dive.

1

Honored to be sharing how Value Base Care (VBC) is an approach to health care management that represents a paradigm shift. At FTI Consulting, we believe that successful VBC adoption necessitates changes in how healthcare organizations perform and manage critical functions (read more below).

69

2 Comments

Discover the reasons behind the $135B decline in UK M&A deal value in 2023 by watching our webinar recording featuring Bain's M&A experts, Peter Horsley and Suzanne Kumar, as they delve into Global and UK M&A industry insights.

4

With the Jefferies Healthcare conference taking place in London last week, the potential of the most exciting innovations and tackling the most pressing industry challenges were top of mind for many. GLP1s, AI, growing investor confidence in the healthcare / biotech market…all leaning towards greater optimism for the life sciences sector in 2025. Sharing Jefferies Temperature Check - check out the summary of key stats if you have only a couple of minutes to scroll….but the full report is definitely worth a read too- both to better understand the opportunities but also to reflect on what problems still need solving for. #strategicpositioning #lifesciences #pharma #biotech #leadership #strategiccommunications

3

In our latest issue of Private Equity Insights, we take a close look at how leaders can affect change. Our new Global Board Governance Survey provides insights regarding the board’s priorities, performance and governance practices from the different perspectives of executive leaders.

5

Corporate Venture Capital (CVC) investments play a pivotal role in driving innovation in the GCC, with a substantial impact on sustainable growth and prosperity. Discover how CVC is shaping our future in our latest report: https://pwc.to/3WrPoht #corporateventures #ventures #investments

20

Amid tightening budgets, 50% of the top 20 leading pharma firms are prioritizing technology to achieve efficiency gains, as pressures on clinical services spending continue to grow. Uncover strategies for life sciences service providers to drive performance in a challenging market environment. https://atbain.co/3V0Ve7X

4

Unlocking Clinical Innovation: Key Insights from Our Roundtable Last week, our Clinical Innovation Roundtable convened at the Kearney London offices. Alongside luminaries Terttu Haring, James Gallagher, Alexander Krupp and Mark Travers, we delved deep into the ever-evolving landscape of clinical innovation. Here are just a few of the things that resonated with me: R&D’s Dynamic Shift: External asset sourcing is reshaping the game. As innovation leaders, we must navigate complexity with a pragmatic mindset. When to plan ahead? When to seize serendipitous opportunities? It’s a dance we perform with partners who bring fresh collaboration styles. Sites, Our Co-Innovators: Clinical trials can still improve in so many ways. Amidst the pressures faced by clinical staff, sponsors who roll up their sleeves as problem-solvers can turbocharge recruitment and retention. And for some things, we should really see how we jointly enable the sites to drive and deploy their own innovation across trials and sponsors. Immerse to Communicate: Remember learning a foreign language in its native land? Nothing beats immersion. Pharma and Site staff are bridging gaps, creating a shared lexicon. Bring out and connect the "young radicals" on both sides to bring in the disruptive ideas of tomorrow. ROI Beyond Trials: Site engagement isn’t a one-time affair—it’s an ongoing investment. Sponsors increasingly find ways to support sites and exchange with physicians beyond specific trials. Better yet to help prepare these partners for future trials, but smart resource allocation needs to be our compass. Exploring new lands: The drive for access to novel therapies for underserved populations is taking us into new regions and countries. There is so much opportunity there, if we are willing and able to invest the time to train and nurture these new sites. Ongoing site engagement is what ultimately gives us a case to "polish these raw diamonds". And the golden rule: Quantify Excitement! Innovation isn’t risk-free, but articulating benefits is non-negotiable. Hone the skill to translate moonshots into measurable value. These insights fuel our journey toward impactful clinical research and development. Looking forward to keeping this conversation going with our broader community, Marc P. Philipp and Horia Giuglea! #ClinicalInnovation #Pharmaceuticals #ClinicalTrials #ResearchAndDevelopment

62

4 Comments

Transactions can play a significant role in large-scale transformation, presenting a time of intensified focus on change and a heightened sense of ownership and accountability. #M&A #privateequity #transformation #valuecreation https://ow.ly/1qqY50QRY4J

1

Bain’s healthcare private equity midyear update shows a strong rebound in North American deals, heightened interest in large-scale assets and IT investments, and increasing investor focus on India. Read the full update here. https://bit.ly/4e61uSY

1

Amid tightening budgets, 50% of the top 20 leading pharma firms are prioritizing technology to achieve efficiency gains, as pressures on clinical services spending continue to grow. Uncover strategies for life sciences service providers to drive performance in a challenging market environment. https://atbain.co/3AHy5k1

2

Bain’s healthcare private equity midyear update shows a strong rebound in North American deals, heightened interest in large-scale assets and IT investments, and increasing investor focus on India. Read the full update here. https://bit.ly/4g5I6XX

4

Our blog this week is the first of two highlighting three of the six disruptive trends that we believe life sciences enterprises and the other members of the health ecosystem should pay particular attention to. Next week we will cover the remaining three trends. A detailed discussion and supporting evidence on the six trends can be found in Deloitte’s 2024 Global Life Sciences Sector Outlook report, authored by our Global Life Sciences & Health Care Industry Leader, Vicky Levy. Deloitte's considered view is that these trends will likely have a wide ranging global impact and are likely to influence the future growth of life sciences companies. John Haughey James Gregson Colin Terry Gillian W. Nicola Abernethy Terry Koch Emily May Márcia Costa Hanno Ronte Rob Hankey

27

Amidst cost pressures and disruptive technologies, medtech companies are rethinking their strategies. Recent transformations highlight focus on core strengths, AI investments, and innovative deal structures. Key areas: digital value transformation, enterprise agility, and M&A strategy. Check out PwC’s latest report here: https://pwc.to/3Yoqgsk #MTC24 #MedtechIndustry #HealthcareTransformation #FutureGrowth

6

KKR is nearing a deal to acquire Healthcare Global Enterprises Limited Global Enterprises Ltd (HCG), India's largest specialty cancer care hospital chain, from CVC  The transaction, expected to close in early 2025, highlights KKR's return to the Indian healthcare market after a two-year hiatus. As part of the acquisition, KKR plans to increase its stake through an open offer, potentially gaining control and driving further growth in India's cancer care sector. The deal follows a successful period of expansion for HCG, which is well-positioned for continued growth in the sector. #Healthcare #PrivateEquity #CancerCare #HCG #KKR #Investment #MergersAndAcquisitions #IndianHealthcare #HospitalSector #GrowthOpportunities

6